A phase 1b study of necitumumab in combination with abemaciclib in patients with stage IV non-small cell lung cancer - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue Lung Cancer Année : 2019

A phase 1b study of necitumumab in combination with abemaciclib in patients with stage IV non-small cell lung cancer

Résumé

Necitumumab, an anti-EGFR antibody, and abemaciclib, a CDK4/6 inhibitor, have shown activity in patients with non-small cell lung cancer (NSCLC) and have non-overlapping toxicities. A 2-part, single-arm, multicenter, phase 1b trial was conducted to test the safety and efficacy of necitumumab plus abemaciclib in patients with advanced NSCLC who had received ≤2 lines of chemotherapy, including a platinum-based one.

Dates et versions

hal-02505039 , version 1 (11-03-2020)

Identifiants

Citer

Benjamin Besse, Fabrice Barlesi, Ingel Demedts, Jose Fuentes Pradera, Gilles Robinet, et al.. A phase 1b study of necitumumab in combination with abemaciclib in patients with stage IV non-small cell lung cancer. Lung Cancer, 2019, 137, pp.136-143. ⟨10.1016/j.lungcan.2019.09.002⟩. ⟨hal-02505039⟩
32 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Mastodon Facebook X LinkedIn More